Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Astrana Health ( (ASTH) ).
On June 4, 2025, Astrana Health, Inc. updated its corporate presentation for use in upcoming conferences and meetings. The presentation materials are provided as part of a Current Report on Form 8-K, but the company has clarified that this information is not to be considered filed under the Securities Exchange Act of 1934, nor will it be updated or incorporated into future filings. This move indicates a strategic effort to engage stakeholders while managing regulatory obligations.
The most recent analyst rating on (ASTH) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Astrana Health stock, see the ASTH Stock Forecast page.
Spark’s Take on ASTH Stock
According to Spark, TipRanks’ AI Analyst, ASTH is a Outperform.
Astrana Health demonstrates robust financial health, with impressive revenue growth and strategic expansions supporting its future prospects. While technical indicators suggest caution due to current price trends, the company’s positive earnings call and strategic corporate events bolster confidence. However, valuation concerns and potential regulatory challenges temper the outlook, resulting in a balanced overall score.
To see Spark’s full report on ASTH stock, click here.
More about Astrana Health
Average Trading Volume: 306,283
Technical Sentiment Signal: Sell
Current Market Cap: $1.22B
For an in-depth examination of ASTH stock, go to TipRanks’ Stock Analysis page.